Research Article
Identifying Risk Factors for Aspiration in Patients Hospitalized with Community-Acquired Pneumonia
Table 4
Antibiotic treatment in AP and non-AP patients.
| | | AP | Non-AP |
| | Percentage of antibiotics usage, N (%) | | Overall antibiotics | 2,676 (92.8) | 52,692 (97.9) | | Broad-spectrum antibiotics | 2,625 (98.1) | 51,972 (98.6) | | Antibiotics for injection | 2,619 (97.9) | 52,093 (98.9) | | Combined antibiotics | 2,187 (81.7) | 40,047 (76.0) | | The top ten antibiotics (%) | | 1 | Piperacillin (44.6) | Moxifloxacin (31.7) | | 2 | Meropenem (24.8) | Levofloxacin (29.9) | | 3 | Levofloxacin (22.9) | Piperacillin (26.3) | | 4 | Moxifloxacin (20.2) | Azithromycin (11.8) | | 5 | Cefoperazone (17.9) | Meropenem (11.3) | | 6 | Vancomycin (13.5) | Cefdinir (10.3) | | 7 | Imipenem (12.9) | Cefoperazone (10.3) | | 8 | Cefixime (9.2) | Cefixime (8.7) | | 9 | Latamoxef (9.1) | Ceftazidime (8.4) | | 10 | Etimicin (8.6) | Imipenem (7.9) |
|
|
